(Q24198135)

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

A randomized double-blinded placebo-controlled crossover trial of nebulized taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Randomized double-blind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Evidence of transmission ofBurkholderia cepacia,Burkholderia multivoransandBurkholderia dolosaamong persons with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Airway surface dehydration in cystic fibrosis: pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Taxonomy and identification of the Burkholderia cepacia complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Psychological consequences of segregation resulting from chronic Burkholderia cepacia infection in adults with CF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Burkholderia cepacia in cystic fibrosis. Variable disease course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Development of a disease specific health related quality of life measure for adults and adolescents with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Successful treatment of cepacia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Microbial ecology of the cystic fibrosis lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Immunological localization of cystic fibrosis candidate gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Pseudomonas cepacia infection in cystic fibrosis: an emerging problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Pathogenicity, virulence factors, and strategies to fight against Burkholderia cepacia complex pathogens and related species

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Combination aerosol therapy to treat Burkholderia cepacia complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Antibiotic allergy in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Cable (cbl) type II pili of cystic fibrosis-associated Burkholderia (Pseudomonas) cepacia: nucleotide sequence of the cblA major subunit pilin gene and novel morphology of the assembled appendage fibers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov. and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Taxon K, a complex within the Burkholderia cepacia complex, comprises at least two novel species, Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Correlation of wbiI genotype, serotype, and isolate source within species of the Burkholderia cepacia complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Cepacia-like syndrome caused by Burkholderia multivorans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Epidemiology ofBurkholderia cepaciacomplex colonisation in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

7 January 2021

A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

7 January 2021

Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

7 January 2021

Randomized trial of ceftazidime versus placebo in the management of acute respiratory exacerbations in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

7 January 2021

[Aminoglycosides in patients with mucoviscidosis and pulmonary exacerbation. Comparison of once or three times daily administration]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

7 January 2021

Outbreak of Pseudomonas cepacia Bacteremia in Oncology Patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

7 January 2021

Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

7 January 2021

Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

7 January 2021

Response of Pseudomonas cepacia to beta-Lactam antibiotics: utilization of penicillin G as the carbon source

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

7 January 2021

Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

7 January 2021

Impact ofBurkholderiaInfection on Lung Transplantation in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

7 January 2021

Colonization of the respiratory tract with Pseudomonas cepacia in cystic fibrosis. Risk factors and outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009529.PUB2

7 January 2021

10.1002/14651858.CD009529.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

23076960

1 reference

Consolidated OpenCitations Corpus – April 2017